Former Cubist chief executive Michael Bonney to chair board at Alnylam
pharmafile | December 22, 2015 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Alnylam, David Pyott, michael bonney
Michael Bonney, current board member and former chief executive of Cubist Pharmaceuticals, has been appointed as chairman of Alnylam Pharmaceuticals effective January 1, 2016.
Founding investor and current chairman John Clarke will remain on the board as a director at the company, which specialises in RNAi therapeutics.
John Maraganore, chief executive at Alnylam, says: “We are indebted to John Clarke, one of our company’s founding investors, for his service as chairman for the past thirteen years, and now welcome Mike Bonney to his newly appointed role leading the board through our transition toward a commercial stage company. Mike led the transition of Cubist from a research and development company to a successful commercial enterprise, and we welcome the leadership he’ll bring to our Board.”
Bonney served as chief executive and a member of the board of directors of Cubist Pharmaceuticals, which became a subsidiary of MSD in January 2015, from June 2003 until his retirement on December 31, 2014. He had been Cubist’s president and chief operating officer from January 2002 to June 2003, and before this he held various positions of increasing responsibility at Biogen, and at Zeneca Pharmaceuticals.
Also, former Allergan chief executive David Pyott will join the board at Alnylam, effective immediately. He served as chief executive of Allergan from 1998 to 2015, where he was recognised by the Harvard Business Review as one of The 100 Best Performing CEO’s in the World.
Maraganore adds: “We’re also very pleased to welcome David Pyott to our Board. David is a highly accomplished industry leader who grew Allergan exponentially during his 17 year tenure. David’s commercial expertise and experience in organisational scaling will be invaluable to Alnylam as we become a commercial biopharmaceutical company.”
Related Content
Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension
Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the …
Alnylam shares positive results from phase 1 trial
Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of …
Alnylam’s lumasiran hits main Phase 3 goal in rare renal disease primary hyperoxaluria type 1
Alnylam has presented promising new Phase 3 data at the European Renal Association-European Dialysis and …
